Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
Dermata Therapeutics (NASDAQ:DRMA) has received a patent grant from the Australian Patent Office for its DMT410 program, which uses Spongilla technology to topically deliver botulinum toxin for treating hyperhidrosis. This marks the company's second granted patent for DMT410.
The patent, titled "Compositions for the treatment of skin conditions" (No. 2109284621), strengthens Dermata's global intellectual property portfolio. The company has recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 specifically for axillary hyperhidrosis treatment, with potential applications for palmer and plantar hyperhidrosis.
Dermata Therapeutics (NASDAQ:DRMA) ha ottenuto un brevetto dall'Ufficio Brevetti Australiano per il suo programma DMT410, che utilizza la tecnologia Spongilla per somministrare topicamente la tossina botulinica nel trattamento dell'iperidrosi. Questo rappresenta il secondo brevetto concesso all'azienda per il DMT410.
Il brevetto, intitolato "Composizioni per il trattamento delle condizioni cutanee" (N. 2109284621), rafforza il portafoglio di proprietà intellettuale globale di Dermata. Recentemente, la società ha stipulato un Accordo di Collaborazione per Studi Clinici con Revance per studiare il DMT410 specificamente nel trattamento dell'iperidrosi ascellare, con possibili applicazioni anche per l'iperidrosi palmare e plantare.
Dermata Therapeutics (NASDAQ:DRMA) ha recibido la concesión de una patente por parte de la Oficina de Patentes de Australia para su programa DMT410, que utiliza la tecnología Spongilla para administrar tópicamente la toxina botulínica en el tratamiento de la hiperhidrosis. Este es el segundo patente otorgada a la compañía para DMT410.
La patente, titulada "Composiciones para el tratamiento de afecciones cutáneas" (N.º 2109284621), fortalece la cartera global de propiedad intelectual de Dermata. Recientemente, la empresa firmó un Acuerdo de Colaboración para Ensayos Clínicos con Revance para estudiar DMT410 específicamente para el tratamiento de la hiperhidrosis axilar, con posibles aplicaciones en la hiperhidrosis palmar y plantar.
Dermata Therapeutics (NASDAQ:DRMA)는 스퐁길라 기술을 이용해 국소적으로 보툴리눔 독소를 전달하는 DMT410 프로그램에 대해 호주 특허청으로부터 특허를 취득했습니다. 이는 DMT410에 대한 회사의 두 번째 특허 승인입니다.
"피부 질환 치료용 조성물"이라는 제목의 특허(번호 2109284621)는 Dermata의 글로벌 지적 재산권 포트폴리오를 강화합니다. 회사는 최근 DMT410을 겨드랑이 다한증 치료에 대해 연구하기 위해 Revance와 임상 시험 협력 계약을 체결했으며, 손바닥 및 발바닥 다한증에 대한 잠재적 적용도 기대하고 있습니다.
Dermata Therapeutics (NASDAQ:DRMA) a obtenu un brevet de l'Office des brevets australien pour son programme DMT410, qui utilise la technologie Spongilla pour administrer localement la toxine botulique dans le traitement de l'hyperhidrose. Il s'agit du deuxième brevet délivré à la société pour le DMT410.
Le brevet, intitulé « Compositions pour le traitement des affections cutanées » (n° 2109284621), renforce le portefeuille mondial de propriété intellectuelle de Dermata. La société a récemment conclu un accord de collaboration pour un essai clinique avec Revance afin d'étudier le DMT410 spécifiquement pour le traitement de l'hyperhidrose axillaire, avec des applications potentielles pour l'hyperhidrose palmaire et plantaire.
Dermata Therapeutics (NASDAQ:DRMA) hat vom australischen Patentamt ein Patent für sein DMT410-Programm erhalten, das die Spongilla-Technologie zur topischen Verabreichung von Botulinumtoxin zur Behandlung von Hyperhidrose einsetzt. Dies ist das zweite erteilte Patent des Unternehmens für DMT410.
Das Patent mit dem Titel "Zusammensetzungen zur Behandlung von Hauterkrankungen" (Nr. 2109284621) stärkt das globale geistige Eigentumsportfolio von Dermata. Das Unternehmen hat kürzlich eine Klinische Studienkooperationsvereinbarung mit Revance abgeschlossen, um DMT410 speziell zur Behandlung der axillären Hyperhidrose zu untersuchen, mit potenziellen Anwendungen bei palmaren und plantaren Hyperhidrosen.
- Second patent grant strengthens global intellectual property protection for DMT410
- Clinical Trial Collaboration Agreement with Revance enhances development prospects
- Potential expansion into palmer and plantar hyperhidrosis markets represents additional opportunities
- Product still in development phase with no immediate revenue potential
- Clinical trials and regulatory approvals still pending
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -
- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -
SAN DIEGO, CA / ACCESS Newswire / July 8, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced the Australian Patent Office has granted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Australian Patent No. 2109284621) continues to strengthen Dermata's global intellectual property portfolio for DMT410 for the treatment of hyperhidrosis.
"We are thrilled to be granted this Australian patent, a testament to our team's relentless innovation and dedication to providing patients with unique and novel treatment options," said Gerry Proehl, Dermata's Chairman, President, and CEO. "We believe this patent reinforces our commitment to pushing boundaries for standard of care for hyperhidrosis patients and delivering groundbreaking solutions that we believe can transform the lives of patients. We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis, as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis, which remain high unmet needs for patients," Mr. Proehl added.
About DMT410
DMT410 is the Company's combination treatment regimen that uses the unique mechanical features of the Company's XYNGARI™ product candidate to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle. The treatment consists of an initial topical application of XYNGARI™ to the treatment area where the microscopic spicules penetrate the stratum corneum to create microchannels into the dermis allowing for the topical application and penetration of botulinum toxin. The Company has successfully completed proof-of-concept Phase 1 clinical trials using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis and for the treatment of multiple aesthetic skin conditions. Both studies showed promising efficacy results and appeared to be safe and well tolerated by patients. The Company is also planning to initiate a Phase 2a study of DMT410 (XYNGARI™ with DAXXIFY®) for the treatment of axillary hyperhidrosis.
About Dermata Therapeutics
Dermata Therapeutics is a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications. Dermata's lead product candidate, XYNGARI™ (formerly DMT310), is its first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a once-weekly, topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action that recently achieved positive data in a Phase 3 STAR-1 study for the treatment of moderate-to-severe acne. In addition to acne, XYNGARI™ has been studied for the treatment of psoriasis and rosacea. Dermata's second program, DMT410, uses XYNGARI™ as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin diseases and conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies, including the FDA; the uncertainties inherent in clinical trials; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidate DMT410 development activities and ongoing and planned clinical trials; whether the results of any planned clinical trials of DMT410 will lead to future product development; whether pending patent applications will proceed to allowance without interruption, if at all; and whether pending, accepted, or issued patents will provide adequate protection for the Company's product candidates, if approved. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire
FAQ
What patent did Dermata (NASDAQ:DRMA) receive for its hyperhidrosis treatment?
What is DMT410's potential market application for Dermata (DRMA)?
Who is Dermata collaborating with for the DMT410 clinical trials?
How many patents does Dermata now have for its DMT410 hyperhidrosis treatment?
